Developmental therapeutics for inflammatory breast cancer: Biology and translational directions

Ricardo Costa*, Cesar A. Santa-Maria, Giovanna Rossi, Benedito A. Carneiro, Young Kwang Chae, William J. Gradishar, Francis J. Giles, Massimo Cristofanilli

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

13 Scopus citations


Inflammatory breast cancer (IBC) is a rare and aggressive form of breast cancer, which accounts for approximately 3% of cases of breast malignancies. Diagnosis relies largely on its clinical presentation, and despite a characteristic phenotype, underlying molecular mechanisms are poorly understood. Unique clinical presentation indicates that IBC is a distinct clinical and biological entity when compared to non- IBC. Biological understanding of non-IBC has been extrapolated into IBC and targeted therapies for HER2 positive (HER2+) and hormonal receptor positive non-IBC led to improved patient outcomes in the recent years. This manuscript reviews recent discoveries related to the underlying biology of IBC, clinical progress to date and suggests rational approaches for investigational therapies.

Original languageEnglish (US)
Pages (from-to)12417-12432
Number of pages16
Issue number7
StatePublished - 2017


  • Immunotherapy
  • Inflammatory breast cancer
  • Targeted therapy

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Developmental therapeutics for inflammatory breast cancer: Biology and translational directions'. Together they form a unique fingerprint.

Cite this